Article
Infectious Diseases
Rosa Maria Vivanco-Hidalgo, Israel Molina, Elisenda Martinez, Ramon Roman-Vinas, Adrian Sanchez-Montalva, Joan Fibla, Caridad Pontes, Cesar Velasco Munoz
Summary: The study found that patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 or hospitalization compared with controls. Although the exposed cohort appeared to have a higher hospitalization rate, this difference was not confirmed after adjustment.
Review
Virology
Xizhong Cui, Junfeng Sun, Samuel J. Minkove, Yan Li, Diane Cooper, Zoe Couse, Peter Q. Eichacker, Parizad Torabi-Parizi
Summary: A systematic review of previous clinical studies found that the use of chloroquine and hydroxychloroquine for non-SARS-CoV2 viral infections did not support their use in the current outbreak of SARS-CoV2.
REVIEWS IN MEDICAL VIROLOGY
(2021)
Review
Rheumatology
Bugra Han Egeli, Jeffrey A. Sparks, Alfred H. J. Kim, Jean W. Liew
Summary: The use of antimalarials for COVID-19 has sparked numerous studies, with early small observational studies influencing treatment strategies, but later larger studies and randomized controlled trials revealing significant contrasts, as well as emerging cardiovascular risks associated with antimalarial use in COVID-19. These studies provide us with more insights into the use of antimalarials in COVID-19 treatment.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
(2021)
Review
Toxicology
Cassandra Doyno, Diana M. Sobieraj, William L. Baker
Summary: Hydroxychloroquine and chloroquine have drawn attention for their potential use in treating COVID-19, but they may cause various toxic reactions, including gastrointestinal issues, cardiotoxicity, dermatologic reactions, and neuropsychiatric symptoms. Long-term use may lead to retinopathy, neuro-myo-toxicity, and cardiotoxicity.
CLINICAL TOXICOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka Asato, Jucineide Vieira Araujo, Adriana de Lima Moreira, Alexia Mahara Marques Araujo, Artur Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella, Frank Silas Saldanha Marques, Gabriel Melo Alexandre Silva, Joana de Sousa Resende, Marycassiely Rodrigues Tizolim, Poliana Lucenados Santos, Steffi Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos Cruz Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza, Allex Jardim da Fonseca
Summary: Despite the favorable safety profile, chloroquine, hydroxychloroquine, or ivermectin do not reduce the need for supplemental oxygen, ICU admission, invasive ventilation, or death in patients hospitalized with severe COVID-19.
PATHOGENS AND GLOBAL HEALTH
(2021)
Article
Cardiac & Cardiovascular Systems
Mavra Viana Rego Souza-Silva, Daniella Nunes Pereira, Magda Carvalho Pires, Isabela Muzzi Vasconcelos, Alexandre Vargas Schwarzbold, Diego Henrique de Vasconcelos, Elayne Crestani Pereira, Euler Roberto Fernandes Manenti, Felicio Roberto Costa, Filipe Carrilho de Aguiar, Fernando Anschau, Frederico Bartolazzi, Guilherme Fagundes Nascimento, Heloisa Reniers Vianna, Joanna d'Arc Lyra Batista, Juliana Machado-Rugolo, Karen Brasil Ruschel, Maria Angelica Pires Ferreira, Leonardo Seixas de Oliveira, Luanna Silva Monteiro Menezes, Patricia Klarmann Ziegelmann, Marcela Goncalves Trindade Tofani, Maria Aparecida Camargos Bicalho, Matheus Carvalho Alves Nogueira, Milton Henriques Guimaraes-Junior, Rubia Laura Oliveira Aguiar, Danyelle Romana Alves Rios, Carisi Anne Polanczyk, Milena Soriano Marcolino
Summary: This study conducted in Brazil found that hydroxychloroquine and chloroquine, although not proven to be beneficial for COVID-19 treatment, were widely prescribed. COVID-19 patients treated with these medications had a longer hospital length of stay compared to matched controls, but there were no significant differences in intensive care unit admission, invasive mechanical ventilation, dialysis, and in-hospital mortality.
ARQUIVOS BRASILEIROS DE CARDIOLOGIA
(2023)
Article
Rheumatology
Stefania Spila Alegiani, Salvatore Crisafulli, Paolo Giorgi Rossi, Pamela Mancuso, Carlo Salvarani, Fabiola Atzeni, Rosa Gini, Ursula Kirchmayer, Valeria Belleudi, Peter Konstantin Kurotschka, Olivia Leoni, Monica Ludergnani, Eliana Ferroni, Susanna Baracco, Marco Massari, Gianluca Trifiro
Summary: The study found that the use of rheumatic drugs does not reduce the risk of COVID-19 hospitalization and mortality, and the use of other rheumatic drugs may increase the risk when compared to non-use.
Article
Public, Environmental & Occupational Health
N. Vieux, Q. Perrier, P. Bedouch, O. Epaulard
Summary: This study aims to compare the state of science before April 2020 regarding the benefits of (H)CQ for viral infections with the number and size of clinical trials studying (H)CQ and the volume of (H)CQ dispensed in France. The results show that the number and size of (H)CQ clinical trials for COVID-19 launched in 2020 were not supported by the literature published before April 2020.
Article
Pharmacology & Pharmacy
Latifa Ait Moussa, Amina Tebaa, Loubna Alj, Houda Sefiani, Fatima Zahra Meski, Asmae Khattabi, Rachida Soulaymani Bencheikh
Summary: This study aimed to describe the distribution, nature, and seriousness of adverse drug reactions (ADRs) associated with the off-label use of chloroquine/hydroxychloroquine + azithromycin for COVID-19 treatment in Morocco. The findings suggest that while ADRs mainly affected the gastrointestinal and nervous systems, the risk of serious ADRs was relatively low. However, caution should be taken in using these drug combinations in diabetic patients to prevent the risk of serious ADRs.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Oncology
Nagla Abdel Karim, Asad Ullah, Imran Ahmad, Elmustapha Bahassi, Olugbenga Olowokure, Ahmed Khaled, Harold Davis, John C. Morris
Summary: Autophagy is a process that helps cells survive during stressful conditions or attacks from chemotherapy or radiation. In this study, the safety and efficacy of combining chloroquine or hydroxychloroquine with carboplatin and gemcitabine in patients with advanced solid tumors were evaluated.
FRONTIERS IN ONCOLOGY
(2022)
Article
Public, Environmental & Occupational Health
Scott M. Vouri, Thuy N. Thai, Almut G. Winterstein
Summary: This study compared the risk of cardiac adverse events when using combinations of chloroquine with azithromycin or amoxicillin. The results showed that the combination of routine doses of chloroquine and azithromycin did not significantly increase arrhythmias in a real-world population, but the conclusions were limited due to a small sample size and outcome rates. Further research is needed.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY
(2021)
Review
Infectious Diseases
Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud, Matthieu Mulot, Nathan Peiffer-Smadja, Yahya Mahamat-Saleh
Summary: This systematic review and meta-analysis found that hydroxychloroquine alone did not reduce mortality in hospitalized COVID-19 patients, while the combination of hydroxychloroquine and azithromycin significantly increased mortality.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Pharmacology & Pharmacy
Emilien Schultz, Laetitia Atlani-Duault, Patrick Peretti-Watel, Jeremy K. Ward
Summary: This study investigated the factors influencing the public perception of the efficacy of hydroxychloroquine (HCQ) in France and found associations with political orientation, trust in government and science, and political engagement. The majority of respondents were uncertain, and media coverage of scientific controversies may have lasting impacts on attitudes towards science and medicine.
Review
Cardiac & Cardiovascular Systems
Prasiddha Parthasarathy, Haniah Shaikh, Paul MacDaragh Ryan, Tapas Mondal
Summary: This review examines the risk of QTc prolongation and arrhythmia in pediatric patients treated with hydroxychloroquine or chloroquine. The findings suggest that while some children may experience QTc prolongation, it is rarely clinically relevant or arrhythmogenic with short-term treatment.
PROGRESS IN PEDIATRIC CARDIOLOGY
(2022)
Article
Multidisciplinary Sciences
Jaishree Mendiratta, Ravi N. Vaswani, Gayatri Saberwal
Summary: In multinational trials conducted in India, there are some trials with planned or actual over-recruitment of participants from India, leading to potential unfairness to Indian participants and the population. Additionally, there are delays in updating completed study records in the Clinical Trials Registry-India (CTRI).
